Bureaucrats, editor, reviewer, Administrators
5,246
edits
ALLHAT: Difference between revisions
Jump to navigation
Jump to search
misc fixes including N/n issue
(misc fixes including N/n issue) |
|||
| Line 17: | Line 17: | ||
| otherSubspecialty1=Cardiology | | otherSubspecialty1=Cardiology | ||
| disease=Hypertension | | disease=Hypertension | ||
| briefDesignDescription=Chlorthalidone vs. amlodipine vs lisinopril | | briefDesignDescription=Chlorthalidone vs. amlodipine vs. lisinopril | ||
| briefResultsDescription=Chlorthalidone is superior | | briefResultsDescription=Chlorthalidone is superior | ||
| trainingLevel=Medical Student | | trainingLevel=Medical Student | ||
| Line 23: | Line 23: | ||
==Purpose== | ==Purpose== | ||
To compare therapy with a calcium channel blocker, ACE | To compare therapy with a calcium channel blocker, ACE inhibitor, or diuretic in lowering the incidence of CV events. | ||
==Major points== | ==Major points== | ||
| Line 29: | Line 29: | ||
==Design== | ==Design== | ||
* Randomized, double-blind, clinical trial conducted from February 1994 through March 2002 | * Randomized, double-blind, clinical trial conducted from February 1994 through March 2002 with an intention-to-treat analysis | ||
* | * n=33,357 (15,255 chlorthalidone vs. 9,048 amlodipine vs. 9,054 lisinopril) | ||
* Recruited at 623 centers in US, Canada, Puerto Rico, and US Virgin Islands between February 1994 through January 1998 | * Recruited at 623 centers in US, Canada, Puerto Rico, and US Virgin Islands between February 1994 through January 1998 | ||
* Mean follow-up: 4.9 years | * Mean follow-up: 4.9 years | ||
==Enrollment criteria== | ==Enrollment criteria== | ||
===Inclusion criteria=== | ===Inclusion criteria=== | ||
* Age | * Age ≥55 years | ||
* Stage 1 or 2 HTN with at least 1 additional risk factor for CHD events, such as: | * Stage 1 or 2 HTN with at least 1 additional risk factor for CHD events, such as: | ||
** | ** Previous (>6 months) MI or stroke | ||
** LVH demonstrated by EKG or echocardiography | ** LVH demonstrated by EKG or echocardiography | ||
** History of T2DM | ** History of T2DM | ||
** | ** Current cigarette smoking | ||
** HDL | ** HDL <35 mg/dL | ||
** | ** Documentation of other atherosclerotic CVD | ||
===Exclusion criteria=== | ===Exclusion criteria=== | ||
* History of hospitalized or treated symptomatic HF and/or known LVEF | * History of hospitalized or treated symptomatic HF and/or known LVEF <35% | ||
==Procedures== | ==Procedures== | ||
* Participants continued any prior antihypertensive medications until they received randomized study drug, at which point they stopped taking all previous medications | * Participants continued any prior antihypertensive medications until they received randomized study drug, at which point they stopped taking all previous medications | ||
* Randomly assigned to chlorthalidone, amlodipine, or lisinopril in a ratio of 1.7:1:1 | * Randomly assigned to chlorthalidone, amlodipine, or lisinopril in a ratio of 1.7:1:1 | ||
* Goal BP | * Goal BP <140/90 mmHg achieved by: | ||
** Step 1: titrating assigned study drug | ** Step 1: titrating assigned study drug | ||
*** 12.5 to 25 mg/d for chlorthalidone | *** 12.5 to 25 mg/d for chlorthalidone | ||